INDBInternet News Database 2.5 Updated 1 min ago · 454 sources Show or hide images Light or dark

Late-Stage Sickle Cell Disease Study Splits on Main Goals

1 source1 article First seen Updated United States Truth score 38

Save Like Comments Compare coverage
Image from Medpagetoday

Summary

(MedPage Today) -- The thalassemia drug mitapivat (Aqvesme) significantly improved hemoglobin response in patients with sickle cell disease but failed to top placebo when it came to reducing pain crises in a phase III trial that aims to support...

Description from Medpagetoday.

Who is covering this

  1. Medpagetoday Center Factuality: Mostly factual US
    Late-Stage Sickle Cell Disease Study Splits on Main Goals

    (MedPage Today) -- The thalassemia drug mitapivat (Aqvesme) significantly improved hemoglobin response in patients with sickle cell disease but failed to top placebo when it came to reducing pain crises in a phase III trial that aims to support...

Comments

Comments need JavaScript.